Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
Go back to Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway| KARYOPHARM THERAP (NASDAQ: KPTI) | Delayed: 1.79 +0.02 (1.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.77 | 52 Week High | $19.41 | |||
| Open | $1.77 | 52 Week Low | $4.83 | |||
| Day High | $1.84 | P/E | N/A | |||
| Day Low | $1.76 | EPS | $-2.74 | |||
| Volume | 577,790 | |||||
